Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sanofi-Aventis starts Phase II flu jab

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sanofi-Aventis starts Phase II flu jab

142 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste | Omlaag ↓
  1. [verwijderd] 26 september 2008 12:57
    FDA Panel: Data Okay For Next Step In Flu Vaccine > AZNLast update: 9/25/2008 4:51:09 PM

    By Jennifer Corbett Dooren
    Of DOW JONES NEWSWIRES
    WASHINGTON (Dow Jones)--A Food and Drug Administration panel of medical experts said Thursday that preclinical data looking at the safety of cells that could be used to produce a next-generation nasal-spray influenza vaccine by MedImmune Inc. were adequate to support testing in humans. MedImmune, a Gaithersburg, Md., unit of AstraZeneca PLC (AZN), currently uses chicken eggs to grow influenza strains that are used in the company's influenza vaccine. Flu-shot makers, which include Sanofi Pasteur, a unit of Sanofi-Aventis (SNY), GlaxoSmithKline PLC (GSK) and Novartis AG (NVS), also grow strains in chicken eggs. However, U.S. health officials are hoping to eventually move influenza-vaccine production away from egg-based production toward other technologies such as cell-cultures that could offer a faster and more reliable way to make flu vaccines. Most vaccine makers currently have cell-based vaccines at various stages of development. One cell line being tested by vaccine makers was originally derived from dog kidneys. But, because cell-lines are derived from animal tissue, there are remote concerns about whether the cells could produce tumors in vaccine recipients. While most panel members on the FDA's vaccine-advisory committee said the data MedImmune has generated to date about its cell lines were adequate and the company could move to human testing in the development of the vaccine, three of the panel's 13 voting members wanted additional information about the size of certain particles derived from the cells. "It's the unknown that makes us nervous," said Steven Self, a professor at the Fred Hutchinson Cancer Research Center in Seattle. In 2005, another FDA panel of outside medical experts met to discuss the use of cell cultures being developed for influenza vaccines by Novartis and Solvay Pharmaceuticals (SOLB.BT). That panel said the inactivation and purification steps used to produce the vaccine were stringent enough to mitigate potential safety concerns. Flu shots are made using inactive influenza strains while MedImmune's nasal spray is made with altered "live" influenza strains, which is way the issue of cell-line safety was again brought to the panel. In 2006, the U.S. government awarded more than $1 billion in federal contracts to a handful of companies including MedImmune, Novartis and Glaxo to speed the development of cell-based influenza vaccines for use in a flu pandemic or the seasonal flu. Health experts are concerned that the H5N1 virus responsible for avian flu, or a similar virus, could cause the next flu pandemic if it mutates and begins rapidly spreading among humans. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com
  2. flosz 26 september 2008 13:07
    quote:

    Dirk R. Wijnen schreef:

    One cell line being tested by vaccine makers was originally derived from dog kidneys. But, because cell-lines are derived from animal tissue, there are remote concerns about whether the cells could produce tumors in vaccine recipients.

    In 2005, another FDA panel of outside medical experts met to discuss the use of cell cultures being developed for influenza vaccines by Novartis and Solvay Pharmaceuticals (SOLB.BT). That panel said the inactivation and purification steps used to produce the vaccine were stringent enough to mitigate potential safety concerns.
    Ter aanvulling (again).

    Tumorgenicity PER.C6-> MDCK
    Analyst Briefing
    April 27, 2006
    Pagina 51,
    hugin.info/132631/R/1052315/174665.pdf

    FDA slides: www.fda.gov/ohrms/dockets/ac/05/slide...

    scaleability is key!
    www.crucell.com/page/downloads/Goudsm...

    A novel high trough-put assay for influenza virus titration on PER.C6TM suspension cells
    Marzio G., Pau M.G., Lonsdale R., Vooys A., Ophorst A., Oerlemans M., Pasma J., UytdeHaag F., (Crucell Holland BV, Leiden, The Netherlands)

    Reliable methods for the quantification of virus replication are of crucial importance in a variety of studies. Applications include efficacy assessment of antiviral drugs, identification of viral phenotypes with altered replication capacity, and selection of viral strains for vaccine production.

    In the case of influenza virus, a commonly adopted definition of infectious titer is based on the appearance of cytopathic effect in cultured Madin-Darby canine kidney (MDCK) cells. MDCK represents the cell line of choice because of its susceptibility to influenza virus infection that results in the formation of distinct plaques, which can be easily counted. Although sensitive and reliable, the plaque assay on MDCK is time and labor consuming. Moreover, since the appearance of plaques requires several rounds of replication, titers may also reflect the ability of the virus to replicate in MDCK cells rather than the initial number of infectious particles per se.

    Here we describe a novel assay for titer determination of influenza viruses based on PER.C6TM suspension cells and fluocytometry. Our system represents a major improvement over other currently used methods due to its rapidity and ease of execution. Accurate titers can be obtained within three hours using PER.C6™ suspension cells at five hours post infection, as opposed to one week for plaque assay on adherent MDCK cells. Our results show that this system can be applied to A as well as B influenza viruses and that titers truly reflect the number of infection-competent particles in the supernatant.
142 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 915,70 +0,57%
EUR/USD 1,0836 +0,11%
FTSE 100 8.364,12 -0,07%
Germany40^ 18.741,60 +0,33%
Gold spot 2.363,48 -0,63%
NY-Nasdaq Composite 16.801,54 -0,18%

Stijgers

VIVORY...
+52,74%
ASML
+3,23%
HEIJMA...
+2,96%
BESI
+2,70%
Vastned
+2,56%

Dalers

JDE PE...
-1,87%
EBUSCO...
-1,76%
Flow T...
-1,27%
Sligro
-1,26%
NSI
-1,23%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!